我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
90
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
FDA
Food and Drug Administration
- Airway Therapeutics appointed Joe Todisco, Chairman and CEO of CorMedix Inc., to its Board of Directors to support the advancement of zelpultide alfa through late-stage development and commercialization preparation. - Todisco brings over two decades of pharmaceutical industry leadership experience, including expertise in hospital channel commercialization where Airway expects to launch its lead product for bronchopulmonary dysplasia (BPD). - Zelpultide alfa is currently in late-stage clinical development for preventing BPD in very preterm infants, a condition with no approved preventive therapies. - The appointment positions Airway Therapeutics for its next growth phase as it prepares to commercialize its platform biologic across multiple disease settings and age groups.
